The cancer diagnostics market size was USD 124.96 billion in 2021 and is expected to reach USD 258.54 billion by 2030. It is anticipated to grow with a healthy CAGR of 8.4% from 2021 to 2030.
In 2022, the cancer diagnostics market study provides crucial information on market share, market size, growth rate analysis Y-O-Y, production, consumption, and sales analysis for the forecast period 2021 to 2030. The report contains 150+ pages with detailed analysis.
Cancer is one of the leading causes of both illness and death around the world. In controlling these deaths, diagnosis of cancer at an early stage is equally important. At present, most of the death causing types of cancers is lungs, stomach, colorectal, liver, breast, and others. It is estimated that, more than 1.5 million individuals are losing their life in a year due to various kinds of cancer. The screening of the early symptoms is equally important. Technological advancement leads to new different methods for screening individuals. As per the professional, cancer-related death size can become down or the mortality rate can be reduced if the cases can be detected early and get treated on time. A cancer diagnosis can be performed by any one of the methods that depend upon the severity. These methods include a physical exam, laboratory test, biopsy, swab test, imaging test, and others.
Growth Factors
The mortality rate of cancer is comparatively higher than chronic related death. Many key strategies are applied by the governments around the world in order to control cancer. The various awareness programs run by government for controlling tobacco, maintaining physical activity, limit the use of alcohol, vaccination against the HPV, and hepatitis B. The awareness also includes the limited exposure of carcinogen, diet and stress-free related life, effective public health activities, and others. In addition, rising number of cancer patients followed by an increasing number of private diagnostic centers is also considered as one of the major factors for promoting the growth of the market.
Since past couple of years, developing countries like India, China, and Indonesia saw a marked growth in healthcare infrastructure development. This is considered as on one of the major driving factors which promote the growth of the market. However, lacs of diagnostic centers facilities and lack of diagnosis is also considered as one of the major restraining factors which affect the growth of the market.
Market Scope:
Report Highlights | Details |
Market Size | US$ 258.54 Billion by 2030 |
Growth Rate | CAGR of 8.4% From 2022 to 2030 |
Base Year | 2021 |
Historic Data | 2017 to 2021 |
Forecast Period | 2022 to 2030 |
Segments Covered | Test Type, Application |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Regional Snapshots
In North America, cancer is the leading cause of death and at present, lung cancer is the leading cause of death in the U.S. In addition, breast cancer is frequently diagnosed in the North American region. National Cancer Institute stated that the burden of cancer increasing day by day in the U.S. Rising geriatric problem and modern lifestyle is one of the major causes for cancer related death. On the other hand, Europe is mostly affected by the geriatric population with a low birth rate. Countries like Germany, France, and UK population are highly diagnosed with cancer.
High population of China and India provide huge patient base which further promote the growth of the market in the Asia Pacific. The countries like Brazil in the Latin America holds more than the 60% market share of the cancer diagnostic market. The rise of patients in this region compared to the Asia Pacific and Latin America is due to the new screening test. Middle East is showing a substantial amount of treatment in the upcoming years. Thyroid cancer is common in females of Gulf Countries. As per the study, males are mostly suffering from lung cancer in the Gulf countries. However, lack of medical facilities in Africa affects the growth of cancer diagnostic market in this region.
COVID-19 Impact:
The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The cancer diagnostics report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.
Key Players:
The cancer diagnostics market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.
Some of the prominent players in the cancer diagnostics market include:
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Becton, Dickinson and Company
- GE Healthcare
- QIAGEN N.V.
- Abbott Laboratories, Inc.
- Roche Diagnostics
- Siemens Healthcare
- Philips Healthcare
- R. Bard, Inc.
- bioMérieux SA
- NeoGenomics Laboratories, Inc.
- Volpara Solutions Limited
- Hologic Inc.
- Canon Medical Systems Corporation
- PenRad Technologies Inc.
- BioNTech Diagnostics GmbH
- BioGenex
Market Segmentation
By Product
- Consumables
- Antibodies
- Kits & Reagents
- Probes
- Other Consumables
- Instruments
- Pathology-based Instruments
- Slide Staining Systems
- Tissue Processing Systems
- Cell Processors
- PCR Instruments
- NGS Instruments
- Microarrays
- Other Pathology-based Instruments
- Imaging Instruments
- CT Systems
- Ultrasound Systems
- MRI Systems
- Mammography Systems
- Nuclear Imaging Systems
- Biopsy Instruments
By Technology
- IVD Testing
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization (ISH)
- Immunohistochemistry (IHC)
- Next-generation Sequencing (NGS)
- Microarrays
- Flow Cytometry
- Immunoassays
- Other IVD Testing Technologies
- Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Positron Emission Tomography (PET)
- Mammography
- Ultrasound
- Biopsy Technique
By Application
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
By End Use
- Hospitals and Clinics
- Diagnostic Laboratories
- Diagnostic Imaging Centers
- Research Institutes
Regional Segmentation
- North America (U.S. and Canada)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Find More Press Releases at https://www.globenewswire.com/en/search/organization/Precedence%2520Research
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Diagnostics Market
5.1. COVID-19 Landscape: Cancer Diagnostics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Diagnostics Market, By Product
8.1. Cancer Diagnostics Market, by Product Type, 2022-2030
8.1.1. Consumables (Antibodies, Kits & Reagents, Probes, Other Consumables)
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Instruments (Pathology-based Instruments, Slide Staining Systems, Tissue Processing Systems, Cell Processors, Others)
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Imaging Instruments (CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems)
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Biopsy Instruments
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cancer Diagnostics Market, By Technology
9.1. Cancer Diagnostics Market, by Technology, 2022-2030
9.1.1. IVD Testing (PCR, ISH, IHC, NGS, Microarrays, Flow Cytometry, Immunoassays)
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Imaging (MRI, CT, PET, Mammography, Ultrasound)
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Biopsy Technique
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Cancer Diagnostics Market, By Application
10.1. Cancer Diagnostics Market, by Application, 2022-2030
10.1.1. Breast Cancer
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Colorectal Cancer
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Cervical Cancer
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Lung Cancer
10.1.4.1. Market Revenue and Forecast (2019-2030)
10.1.5. Prostate Cancer
10.1.5.1. Market Revenue and Forecast (2019-2030)
10.1.6. Skin Cancer
10.1.6.1. Market Revenue and Forecast (2019-2030)
10.1.7. Blood Cancer
10.1.7.1. Market Revenue and Forecast (2019-2030)
10.1.8. Kidney Cancer
10.1.8.1. Market Revenue and Forecast (2019-2030)
10.1.9. Liver Cancer
10.1.9.1. Market Revenue and Forecast (2019-2030)
10.1.10. Pancreatic Cancer
10.1.10.1. Market Revenue and Forecast (2019-2030)
10.1.11. Ovarian Cancer
10.1.11.1. Market Revenue and Forecast (2019-2030)
10.1.12. Others
10.1.12.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Cancer Diagnostics Market, By End Use
11.1. Cancer Diagnostics Market, by End Use, 2022-2030
11.1.1. Hospitals and Clinics
11.1.1.1. Market Revenue and Forecast (2019-2030)
11.1.2. Diagnostic Laboratories
11.1.2.1. Market Revenue and Forecast (2019-2030)
11.1.3. Diagnostic Imaging Centers
11.1.3.1. Market Revenue and Forecast (2019-2030)
11.1.4. Research Institutes
11.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 12. Global Cancer Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.2. Market Revenue and Forecast, by Technology (2019-2030)
12.1.3. Market Revenue and Forecast, by Application (2019-2030)
12.1.4. Market Revenue and Forecast, by End Use (2019-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.1.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.1.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.1.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.1.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.7.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.7.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.7.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.8.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.8.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.8.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.7.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.7.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.7.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.8.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.8.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.8.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.7.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.7.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.7.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.8.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.8.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.8.4. Market Revenue and Forecast, by End Use (2019-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.5.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.5.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.5.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.5.6.4. Market Revenue and Forecast, by End Use (2019-2030)
Chapter 13. Company Profiles
13.1. Agilent Technologies, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Illumina, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Becton, Dickinson and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GE Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN N.V.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Abbott Laboratories, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Roche Diagnostics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Siemens Healthcare
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Philips Healthcare
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. R. Bard, Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333